Free Trial

Regulus Therapeutics (NASDAQ:RGLS) Raised to "Overweight" at Wells Fargo & Company

Regulus Therapeutics logo with Medical background
Remove Ads

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) was upgraded by stock analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating in a note issued to investors on Thursday, March 27th, MarketBeat Ratings reports. The brokerage presently has a $6.00 price target on the biopharmaceutical company's stock, up from their previous price target of $3.00. Wells Fargo & Company's price objective points to a potential upside of 235.20% from the stock's current price.

Several other research firms also recently commented on RGLS. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $28.00 price objective on shares of Regulus Therapeutics in a research report on Monday, March 17th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $12.75.

Read Our Latest Stock Report on Regulus Therapeutics

Regulus Therapeutics Stock Down 8.7 %

Regulus Therapeutics stock traded down $0.17 during midday trading on Thursday, reaching $1.79. The company's stock had a trading volume of 346,902 shares, compared to its average volume of 655,167. Regulus Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $2.90. The business has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $1.45. The company has a market cap of $118.57 million, a P/E ratio of -1.67 and a beta of 1.42.

Remove Ads

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter in the previous year, the firm earned ($0.40) earnings per share. As a group, equities analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Regulus Therapeutics

In related news, CFO Crispina Calsada sold 38,716 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,782.16. Following the sale, the chief financial officer now owns 50,566 shares of the company's stock, valued at approximately $63,713.16. This represents a 43.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph P. Hagan bought 50,000 shares of Regulus Therapeutics stock in a transaction on Thursday, January 30th. The stock was purchased at an average price of $1.09 per share, for a total transaction of $54,500.00. Following the completion of the acquisition, the chief executive officer now owns 260,808 shares in the company, valued at $284,280.72. This represents a 23.72 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 223,998 shares of company stock valued at $282,237. Corporate insiders own 4.35% of the company's stock.

Institutional Trading of Regulus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Velan Capital Investment Management LP acquired a new stake in Regulus Therapeutics during the 4th quarter worth approximately $111,000. Octagon Capital Advisors LP raised its holdings in shares of Regulus Therapeutics by 13.7% during the 4th quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after buying an additional 585,101 shares during the period. Millennium Management LLC boosted its stake in shares of Regulus Therapeutics by 69.7% in the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after purchasing an additional 900,743 shares during the period. PEAK6 LLC purchased a new stake in shares of Regulus Therapeutics during the fourth quarter worth about $95,000. Finally, Barclays PLC raised its position in shares of Regulus Therapeutics by 13.9% in the 4th quarter. Barclays PLC now owns 96,247 shares of the biopharmaceutical company's stock valued at $152,000 after purchasing an additional 11,770 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

(Get Free Report)

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

Featured Articles

Should You Invest $1,000 in Regulus Therapeutics Right Now?

Before you consider Regulus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.

While Regulus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads